Start in Taiwan, Expand Globally, Develop into an International Brand.
OBI operates with an excellent management team and efficient business model to create an international Taiwan brand, and to base in Taiwan and expand the horizon worldwide.
Courage to innovate
Change the future
Developing novel therapeutic agents for patients with unmet medical needs
What's New?
2025.Jun.10
News
OBI Pharma Showcases Next-Generation ADC Development at 2025 World ADC Asia Summit
Photo credit: Dr. Wei-Han Lee OBI Pharma (4174.TWO) participated in the 4th World ADC Asia Summit, held from June 10 to 12 in Incheon, Korea, with three featured presentations, one expert panel discussion, and three poster sessions—showcasing its latest research achievements in the field of antibody-drug conjugates (ADCs) and demonstrating the growing industry recognition of […]
2025.Jun.06
News
OBI Pharma Enters ADC Collaboration with TegMine Therapeutics utilizing GlycOBI® and TegMiner™ Enabling Technologies
Taipei, Taiwan. June 06, 2025 – OBI Pharma, Inc. (OBI), a clinical-stage global oncology company specialized in the development of novel cancer therapies such as antibody-drug conjugates (ADCs) (4174. TWO), and TegMine Therapeutics, Inc. (TegMine), a US Biopharma specialized in developing best-in-class antibodies targeting cancer glycans and glycoproteins, have entered into an ADC-related Master Services […]
2025.Apr.29
News
OBI Pharma Unveils New ThiOBI® and HYPrOBI™ Platforms
Showcasing Strong ADC Development Capabilities and Captivating Attention at AACR
OBI Pharma (4174.TWO) continues to forge ahead on the global stage, recently debuting its innovative ThiOBI® platform and HYPrOBI™ linker technology at the American Association for Cancer Research (AACR) Annual Meeting. These two independently developed enabling technologies have greatly advanced next-generation antibody-drug conjugate (ADC) development capabilities, captivating attendees and drawing considerable interest and inquiries. The AACR […]
2025.Mar.26
News
OBI Wins " Most Promising Immunotherapy Pipeline" Award
Showcasing TROP2 ADC Research at Biologics World Taiwan
OBI Pharma (4174.TWO) has been recognized as a winner by the Taiwan Biopharma Excellence Awards (TBEA), in the ” Most Promising Immunotherapy Pipeline” award category today (3/26). Following OBI-992’s selection as a Top 8 Finalist in last year’s World ADC Awards and the recent recognition at the ADC Asia Congress 2025 in Singapore on 3/12, […]
2025.Mar.18
News
New Chairman of OBIGEN Pharma: OBI Pharma CEO Heidi Wang Takes Over
Following the resignation of Mr. Frank Chen as Chairman, the board of directors of OBIGEN PHARMA unanimously elected Dr. Heidi Wang, CEO of its parent company, OBI Pharma, to assume the chairmanship of OBIGEN PHARMA today (18th). The position of corporate representative director, previously held by Mr. Frank Chen, has been taken up by Ms. […]
2025.Mar.12
News
OBI Pharma Receives ‘Most Promising ADC Clinical Candidate in Taiwan’ Award
Dr. Heidi Wang Accepts Award on Behalf of OBI Pharma at ADC Asia Congress 2025 and Gives a Presentation
At the ADC Asia Congress 2025 held today (3/12) in Singapore, OBI Pharma (4174.TWO) was honored with the “Most Promising ADC Clinical Candidate in Taiwan” award. This recognition follows OBI Pharma’s achievement last year as a candidate in the World ADC Awards, where it was shortlisted among the top eight international pharmaceutical companies. The award […]
2025.Feb.19
News
Invited to the 2025 Healthcare Conference in Taipei
Dr. Heidi Wang engaged in discussions on Regulatory Landscape and International Partnerships in Pharma and Diagnostics
The highly anticipated Healthcare Conference Taipei 2025 kicked off this Wednesday and Thursday (2/19-2/20). Dr. Heidi Wang, CEO of OBI Pharma (4174.TWO), was invited to participate in the panel discussion on ” Regulatory Landscape and International Partnerships in Pharma and Diagnostics” at the Regent Taipei on 2/19. Co-hosted by University of California, Berkeley School of […]
2024.Dec.31
News
OBI Pharma's OBI-992 Research Paper Featured on Cover and Selected as a First Disclosure Article in Molecular Cancer Therapeutics Journal
OBI Pharma (4174.TWO)’s independent work based on a TROP2-targeted Antibody-Drug Conjugate (ADC) anti-cancer asset, OBI-992, is published on the cover of the internationally renowned journal “Molecular Cancer Therapeutics” (MCT), with the article designated as a First Disclosure recommended publication. Molecular Cancer Therapeutics, a journal of the American Association for Cancer Research (AACR), specializes in preclinical […]
2024.Dec.23
News
OBI Pharma Enters Collaboration with GlyTech to Expand GlycOBI® Enabling Technologies Outreach in Japan and to Advance Glycan Production
Taipei, Taiwan. December 23, 2024 – OBI Pharma, Inc. (OBI), a clinical-stage global oncology company specialized in the development of novel cancer therapies such as antibody-drug conjugates (ADC) and active immunotherapies (4174. TWO), and GlyTech, Inc. (GlyTech), a Japan manufacturer that focuses on glycan production and chemical glycosylation technologies, have entered into a Marketing Agreement […]
2025.Feb.19
News
Invited to the 2025 Healthcare Conference in Taipei
Dr. Heidi Wang engaged in discussions on Regulatory Landscape and International Partnerships in Pharma and Diagnostics
Who We Are